The decrease in spending in 2021 was mainly due to a decrease in pre-launch inventory costs, partially offset by an increase in clinical trial expenses.
The growth in spending was driven by the commercialization of our COVID-19 vaccine globally with continued investments in personnel and outside services in support of the accelerated company buildout.
Retrieved 19 March 2021.
There was a staging link that was being tested earlier.
Retrieved 21 May 2021.
Retrieved 5 November 2021.